__ __ __ __ _____ _ _ _____ _ _ _ | \/ | \ \ / / | __ \ (_) | | / ____| | | | | | \ / |_ __\ V / | |__) | __ ___ ____ _| |_ ___ | (___ | |__ ___| | | | |\/| | '__|> < | ___/ '__| \ \ / / _` | __/ _ \ \___ \| '_ \ / _ \ | | | | | | |_ / . \ | | | | | |\ V / (_| | || __/ ____) | | | | __/ | | |_| |_|_(_)_/ \_\ |_| |_| |_| \_/ \__,_|\__\___| |_____/|_| |_|\___V 2.1 if you need WebShell for Seo everyday contact me on Telegram Telegram Address : @jackleetFor_More_Tools:
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<meta http-equiv="content-type" content="text/html; charset="UTF-8">
<title>Dipirona</title>
<link rel="stylesheet" href="estilo5.css" type="text/css" media="screen">
</head>
<body>
<div id="container">
<div id="header" title="sitename">
<h1 style="text-align: center;"><img style="width: 800px; height: 120px;"
alt="" src="logo.jpg"></h1>
</div>
<div class="blogentry">
<div style="text-align: center;"><iframe src="indice.html" width="800" height="20"
frameborder="0"></iframe></div>
<center><font class="option" color="#000000"><b><br>
</b></font></center>
<br>
<h2 style="text-align: center;" class="art-PostHeader">Dipirona: modo de
a��o analg�sica</h2>
<p>Publicado em 25 de agosto de 2000 | �ltima atualiza��o: 5 de dezembro
de 2015</p>
<div style="text-align: justify;">
<div style="text-align: justify;"><span style="font-weight: bold;">1 -
INTRODU��O<br>
<br>
</span></div>
Analgesia por analg�sicos e anti-inflat�rios n�o esteroidais (AINEs) �
explicada pela a��o inibit�ria da s�ntese local de prostaglandina-2
(PGE2) (Vane, 1971). Essa a��o previne o desenvolvimento da
hiperalgesia , isto �, a sensibiliza��o dos receptores de dor
para est�mulos qu�micos e f�sicos. </div>
<p style="text-align: justify;">Dipirona � um analg�sico e antipir�tico
muito utilizado em diversos pa�ses onde sua propaganda � permitida.</p>
<p style="text-align: justify;">Existe uma impress�o entre os m�dicos de
que a dipirona tem um efeito cl�nico diferente dos AINEs. Existem
muitos artigos e estudos na literatura mostrando que a dipirona tem
efeito analg�sico maior que aspirina, que � um antiinflamat�rio
inibidor de COX cl�ssico (Mukherjee et Sudha, 1980; Petrova et al.
1980) ou paracetamol (Daftary et al, 1980), um analg�sico do grupo da
anilina, e por isso o perfil do efeito farmacol�gico da dipirona �
certamente diferente do que dos AINEs e tamb�m dos analg�sicos de a��o
central (Nikolova et al, 1980; Nikolov et al., 1980). No entanto, esse
s�tio de a��o analg�sica � um mecanismo controverso. A a��o central
foi proposta por Von Tomek (1955) e n�o confirmada por Lorenzetti
(1999) que, ao aplicar dipirona intra-cerebroventricular de rato, n�o
conseguiu inibir a hiperalgesia induzida por prostaglandina em pata
trazeira de rato.</p>
<div style="text-align: justify;"></div>
<p style="text-align: justify; font-weight: bold;">2 � O QUE � DIPIRONA</p>
<p style="text-align: justify;">Dipirona � o nome gen�rico de �cido
[(2,3-dihidro-1,5-dimetil-3-oxo-2-fenil-1H-pirazol-4-il)metilamino]metanossulf�nico,
tamb�m
chamado de
1-fenil-2,3-dimetil-5-pirazolona-4-metilaminometanossulfonato de s�dio
(ou de magn�sio), e ainda denominado de metamizol, um segundo nome
gen�rico e muito encontrado na literatura farmacol�gica
norte-americana e europ�ia</p>
<p style="text-align: center;"> <img style="width: 367px; height: 151px;"
title="Dipirona" src="../img/dipirona.jpg" alt="Dipirona"></p>
<p style="text-align: justify;">Com peso molecular de 351,36 e uma
distribui��o relativa de 44,44% de carbono, 5,16% de hidrog�nio,
11,96% de nitrog�nio, 6,54% de s�dio (7,26% se for magn�sio), 22,77%
de oxig�nio e 9,13% de enxofre, apresenta f�rmula emp�rica
C13H16N3NaO4S.H2O (ou C26H32MgN6O8S2. Na dipirona magnesiana ligam-se
duas mol�culas de dipirona ao c�tion magn�sio). � preparada a partir
da metila��o do grupo amino da sulfamipirina, tratada com alde�do
metan�ico (formalde�do ou formol), em solu��o de bissulfito de s�dio.
Muito sol�vel em �gua (1g/1,5ml), � pouco sol�vel em etanol e
praticamente insol�vel em �ter, acetona, benzeno e clorof�rmio, sendo
um complicador quando � necess�rio fazer uma cromatografia de camada
delgada para diferencia��o da dipirona de outros t�xicos e
barbit�ricos em processos jucidiais onde � pedido a identifica��o
toxicol�gica com fins forenses, pois os melhores carreadores de
mol�culas em cromatografia de camada delgada s�o justamente o benzeno,
o �ter, o etanol, o hexano e a acetona, sendo o metanol muito pouco
utilizado devido � sua toxicidade e a �gua n�o ser usada por dissolver
a camada de s�lica da placa.</p>
<p style="text-align: justify;">Observando a mol�cula da dipirona, �
poss�vel identificar duas estruturas ligantes que tem pap�is
importantes no mecanismo de a��o deste f�rmaco. O primeiro � o
grupamento benzoil, que tem atividade anest�sica comprovada, tanto que
a maior contribui��o da coca�na para a farmacol�gia foi a
identifica��o dos componentes de sua f�rmula estrutural e a descoberta
de que, retirando-se o radical benzoil, a coca�na perdia sua a��o
anest�sica (Cavazzani, 1994).</p>
<p style="margin: 0cm 0cm 0.0001pt; text-align: justify; text-indent: 36pt; line-height: 150%;"><span
style="font-family: "Arial","sans-serif"; color: black;"> <o:p></o:p></span></p>
<div style="text-align: center;"><img style="width: 108px; height: 84px;"
title="Benzoil (benzil ou fenil)" src="../img/benzoil.jpg" alt="Benzoil (benzil ou fenil)"><span
style="font-family: "Arial","sans-serif"; color: black;"></span><br>
<span style="font-family: "Arial","sans-serif"; color: black;">
</span></div>
<div style="text-align: justify;"><span style="font-family: "Arial","sans-serif"; color: black;"><br>
</span>Outro ligante de import�ncia na estrutura da dipirona � o
grupamento sulfato, respons�vel por sua alta solubilidade em �gua e
pela sua facilidade de absor��o, � potencilamente agressivo para a
medula �ssea, podendo causar desde neutropenias, agranilocitoses, at�
aplasia de medula �ssea, uma patologia hematopoi�tica muito severa que
s� tem um tratamento, o transplante de medula �ssea que, se n�o
realizado em tempo, pode levar o indiv�duo ao �bito.</div>
<div style="text-align: center;"><img style="width: 104px; height: 120px;"
title="Sulfato" src="../img/sulfato.jpg" alt="Sulfato"><br>
</div>
<br>
<p style="text-align: justify;">Foi patentetada sob n� 254, pelo
Laborat�rio Hoechst em 1911, na Alemanha com o nome de Metamizol� que
hoje acabou virando nome gen�rico, como aconteceu com a Aspirina�, que
� marca registrada de �cido acetilsalic�lico, desenvolvido pela Bayer
e que se consagrou, tornando-se um nome gen�rico.</p>
<p style="text-align: justify; font-weight: bold;">3 � MECANISMO DE A��O</p>
<p style="text-align: justify;">Apesar de todas as pesquisas j�
realizadas apontarem para uma a��o bloqueadora da hiperalgesia
exercida pela liga��o a um receptor perif�rico, combinado com a��o
espinal da dipirona e com poucos efeitos antiedematosos e/ou
antiiflmat�rios, alguns bancos de dados insistem em continuar
afirmando que a a��o da dipirona atua unicamente por inibi��o de
cicloxigenase, inibindo a s�ntese de prostaglandinas (Abbate et al,
1990; Anon, 1973; Reynolds, 1994; Gladtke, 1983; Arellano et
Sacristan, 1990).</p>
<p style="text-align: justify;">No volume 116, de setembro de 2000 do
banco de dados Drugdex (Micromedex) aparece a cita��o feita no
par�grafo anteiror, ignorando os trabalhos realizados entre 1996 e
1999 por Aleksander Zampronio, Berenice B. Lorenzetti e S�rgio H.
Ferreira, que apontam para a a��o perif�rica da dipirona sobre um
receptor sin�ptico com estimula��o epinhal via ativa��o da
arginina/cGMP em neur�nios sensoriais prim�rios.</p>
<p style="text-align: justify;">Em 2014 um grupo de pesquisadores do
Departamento de Biologia Estrutural e Funcional do Instituto de
Biologia da Universidade de Campinas (UNICAMP) publicou um estudo
demonstrando que a dipirona atua sobre um receptor canabinoide da
classe 1, chamado de CB1 (SANTOS et al., 2014) e praticamente
corroborou os resultados do grupo de Ribeir�o Preto acerca do
mecanismo de ativa��o antinociceptiva sobre um neur�nio sensorial
prim�rio e indicou o receptor canabin�ide da classe 1, designado na
literatura como CB1, integrante da fam�lia de receptores acoplados �
prote�na G, inibidores da adenilciclase e de canais de c�lcio (Ca2+)
operados por voltagem como o respons�vel pela liga��o ao f�rmaco e seu
efeito antinociceptivo. <br>
<br>
O grupo da UNICAMP trabalhou com inibi��o da express�o dos receptores
CB1 atrav�s da aplica��o de inje�es intratecais de sequ�ncias
antisense de oligo-deoxinucleot�deos, isoladas atrav�s de
sequenciamento (ORTU�O et al., 2013) do genoma dos animais
experimentais utilizados (ratos), que parece ter elucidado o receptor
da dipirona, mas n�o identificado pelo grupo de Ribeir�o Preto que,
conforme a literatura farmacol�gica, receptores CB1 s�o abundantes no
sistema nervoso central, enquanto os CB2, a outra isoforma de
receptores canabin�ides, predominam nos tecidos perif�ricos (KATZUNG,
2017) e c�lulas do sistema imunol�gico (RANG, H.P, DALE, M. M.,
RITTER, 2016).</p>
<p style="text-align: justify;">At� pouco tempo atr�s a a��o antit�rmica
da dipirona podia ser explicada pelo antagonismo direto de cininas
pirog�nicas em receptores do centro termo-regulador, localizado no
t�lamo, mas em 2015 surgiu um novo estudo corroborando os resultados
do grupo UNICAMP, mas apontando para um efeito antipir�tico da
dipirona quando ligada aos receptores CB1 e n�o demonstrando efeito
analg�sico (CRUNFLI, et al., 2015). O efeito antipir�tico produzido
pela liga��o da dipirona com o receptor CB1 � compat�vel com a
hipotermia produzida pelo tetra-hidrocanabinol da maconha e pode
explicar o efeito antipir�tico da dipirona, podendo esta liga��o
acontecer em tecidos perif�ricos e n�o no sistema nervoso central.</p>
<p style="text-align: justify;"><br>
</p>
<p style="text-align: justify; font-weight: bold;">4 � FARMACOCIN�TICA</p>
<p style="text-align: justify;">4.1 � IN�CIO DA A��O</p>
<p style="text-align: justify;">Na hipertermia (febre), ap�s
administra��o oral, o efeito hipotermiante come�a a aparecer entre 30
minutos e no m�ximo em uma hora (Ajgaonkar et al, 1988; Giovannini et
al, 1986; Reiner et al, 1984). O pico m�ximo de resposta ficam entre 4
e 6 horas (Ajgaonkar et al, 1988; Giovannini et al, 1986; Reiner et
al, 1984).</p>
<p style="text-align: justify;">4.2 � N�VEL M�XIMO DE CONCENTRA��O
PLASM�TICA</p>
<p style="text-align: justify;">Ap�s administra��o oral, pode ser
encontrado um n�vel m�ximo de concentra��o ap�s 1 a 2 horas (Vlahov et
al, 1990; Flusser et al, 1988; Volz et Kellner, 1980). O n�vel m�ximo
de concentra��o plasm�tica do metab�lito ativo 4-MAA encontrado foi de
11, 21 e 41 mcg/ml, ap�s administra��o oral de 750, 1500 e 3000mg de
dipirona, respectivamente (Vlahov et al, 1990). Na realidade e
dipirona � uma pro-droga que � metabolizada no trato intestinal em
4-metilaminoantipirina (4-MAA), o metab�lito ativo (Vlahov et al,
1990; Flusser et al, 1988; Brune, 1988; Levy, 1986; Volz et Kellner,
1980). O 4-MAA � metabolizado no f�gado em 4-aminoantipirina (4-AA),
um segundo metab�lito ativo (Brune, 1988; Flusser et al, 1988).</p>
<p style="text-align: justify;">A dipirona n�o apresenta intera�es
conhecidas com alimentos ou ent�o s�o clinicametne insignificantes
(Levy et al, 1995; Flusser et al, 1988).</p>
<p style="text-align: justify;">4.3 � S�TIOS DE DISTRIBUI��O</p>
<p style="text-align: justify;">Cerca de 58% do 4-MAA e 48% do 4-AA s�o
distribuidos ligados �s prote�nas plasm�ticas (Zylber-Katz et al,
1985). Os metab�litos da dipirona tem sido encontrados no l�quido
c�falo-raquidiano. Em estudo controlado, 28 pacientes com indica��o
terap�utica de dipirona, tomando 1g por via oral (dois comprimidos de
500mg) em tempos diversos (6 em 6 horas) foram submetidos a pun��o
lombar em v�rios intervalos de tempo e colhido cerca de 2ml de l�quor
sendo detectada a presen�a dos metab�litos em concentra��o menor que
no plasma, mas guardando uma propor��o l�quor/plasma de ambos os
metab�litos (Cohen et al, 1998).</p>
<p style="text-align: justify;">4.4 � VOLUME DE DISTRIBUI��O</p>
<p style="text-align: justify;">O volume de distribui��o do 4-MAA � de
40 litros (Vlahov et al, 1990).</p>
<p style="text-align: justify;">4.5 � METABOLISMO</p>
<p style="text-align: justify;">4.5.1 � PAREDE INTESTINAL</p>
<p style="text-align: justify;">A metaboliza��o da dipirona na parede
intestinal � extensa (Vlahov et al, 1990; Flusser et al, 1988; Brune,
1988; Levy, 1986; Volz et Kellner, 1980).</p>
<p style="text-align: justify;">O metabolismo � feito monoenzimaticamene
por hidr�lise no trato intestinal formando o 4-MAA, um dos seus
metab�litos ativos (Vlahov et al, 1990; Flusser et al, 1988; Brune,
1988; Levy, 1986; Volz et Kellner, 1980).</p>
<p style="text-align: justify;">4.5.2 � F�GADO</p>
<p style="text-align: justify;">No f�gado o metabolismo tamb�m � grande
(Flusser et al, 1988; Brune, 1988; Volz et Kellner, 1980). O 4-MAA �
transformado em 4-AA (Brune, 1988; Flusser et al, 1988; Volz et
Kellner, 1980) e outros metab�litos inativos e de pouca import�ncia.
Em portadores assintom�ticos de hepatite B, com fun��o hep�tica
normal, testes demonstraram preju�zo no metabolismo oxidativo da
dipirona quando comparado com sujeitos n�o portadores (Levy et al,
1997).</p>
<p style="text-align: justify;">4.5.3 � METAB�LITOS</p>
<p style="text-align: justify;">1. 4-Metilaminoantipirina, � um
metab�lito ativo (Flusser et al, 1988; Brune, 1988).</p>
<p style="text-align: justify;">2. 4-Aminoantipirina, tamb�m � um
metab�lito ativo (Brune, 1988; Flusser et al, 1988; Volz et Kellner,
1980).</p>
<p style="text-align: justify;">3. 4-Formil-aminoantipirina (4-FAA), �
um metab�lito inativo (Vlahov et al, 1990; Volz et Kellner, 1980).</p>
<p style="text-align: justify;">4. 4-acetilaminoantipirina (4-AcAA),
tamb�m � inativo (Vlahov et al, 1990; Volz et Kellner, 1980).</p>
<p style="text-align: justify;">4.5.4 � EXCRE��O</p>
<p style="text-align: justify;">4.5.4.1 � Leite Materno</p>
<p style="text-align: justify;">Os metab�litos ativos da dipirona, tanto
o 4-MAA, quanto o 4-AA podem ser encontrados em altos n�veis no leite
materno. Est�o em concentra��o igual ou at� maior que no plasma. No
entanto, os metab�litos foram encontrados no leite at� 48 horas ap�s
administra��o �nica de dipirona por via oral , devendo o uso de
dipirona ser evitado durante o aleitamento materno (Zylber-Katz et al,
1986).</p>
<p style="text-align: justify;">4.5.4.2 � Rins</p>
<p style="text-align: justify;">A excre��o renal � intensa, sendo a
maior via de elimina��o (Vlahov et al, 1990; Volz et Kellner, 1980).
Os metab�litos 4-FAA e 4-AcAA s�o excretados primeiramente na urina
(Vlahov et al, 1990; Volz et Kellner, 1980).</p>
<p style="text-align: justify;">4.5.5 � MEIA VIDA</p>
<p style="text-align: justify;">O metab�lito 4-MAA tem uma meia vida de
2 a 3 horas (Vlahov et al, 1990; Volz et Kellner, 1980). O tempo de
elimina��o m�dio do metab�lito 4-MAA � significativamente aumentado
nos portadores assintom�ticos de hepatite B, quando comparado com
indiv�duos sadios. (Levy et al, 1997), enquanto o tempo de meia-vida
de elimina��o do 4-FAA est� significativamente diminuido em portadores
de hepatite B em compara��o com sujeitos n�o portadores. Os tempos de
meia-vida de elimina��o dos metab�litos 4-MAA e 4-AcAA n�o apresentam
diferen�as estat�sticas significantes entre os dois grupos. (Levy et
al, 1997).</p>
<p style="text-align: justify;">O metab�lito 4-AA tem uma meia-vida de
elimina��o de 4 a 5 hoas (Vlahov et al, 1990; Volz et Kellner, 1980).</p>
<p style="text-align: justify; font-weight: bold;">5 � DILUI��O E
ESTABILIDADE</p>
<p style="text-align: justify;">A Dipirona � compat�vel com solu��o
glicosada a 5%, solu��o de NaCl a 0,9%<br>
e Ringer lactato*.<br>
A administra��o deve ser imediata em �bolus� (ou em bolo) j� que a
estabilidade � limitada nas<br>
tr�s solu�es, devendo ser evitada a infus�o cont�nua*.</p>
<p style="text-align: justify;">* Informa�es do fabricante
Aventispharma (fabricante da Novalgina�).<br>
</p>
<p style="text-align: justify; font-weight: bold;">6 � RESTRI��ES AO USO</p>
<p style="text-align: justify;">6.1 � CONTRA-INDICA��ES</p>
<p style="text-align: justify;">Discrasias sangu�neas ou depress�o da
medula �ssea, hipersensibilidade, rinite, urtic�ria, asma e rea�es
al�rgicas � aspirina ou outros agentes antiinflamat�rios.</p>
<p style="text-align: justify;">6.2 � PRECAU��ES</p>
<p style="text-align: justify;">Hist�ria de �lceras gastrointestinais,
hemorragias g�stricas ou perfura�es da mucosa; disfu�es renais;
hipertens�o card�aca (sobrecarga ventricular esquerda) ou disfun�es
card�acas agravadas por reten��o de fluidos e edema; disfu��o
hep�tica; infec�es pr�-existentes; porf�ria; deficiencia de
glicose-6-fosfato desidrogenase e uso concomitante com clorpormazina.</p>
<p style="text-align: justify;">6.3 � REA��ES ADVERSAS</p>
<p style="text-align: justify;">Anemia hemol�tica e aplasia de medula
�ssea tem sido reportada durante o uso de dipirona (Anon, 1986;
Sansone et al, 1984; Lay, 1966). Agranulocitose � a ocorr�ncia mais
frequente durante a administra��o de dipirona e pode ser fatal
(Arellano et Sacristan, 1990; Hargis et al, 1989; Kiatboonsri et
Richter, 1989; Anon, 1986; Gladtke, 1983; Anon, 1973; Bottiger et
Westerholm, 1973; Sadusk, 1965; Huguley, 1964), tendo muitos casos
acontecidos durante 20 anos de uso de dipirona na Holanda (van der
Klauw et al, 1998). A incid�ncia da indu��o de agranulocitose tem
varia��o geogr�fica. Aparece em altas frequ�ncias em Barcelona e
Berlim e em pequnos �ndices em Budapest, Tel-Aviv e Sofia (Anon, 1986;
Arellano et Sacristan, 1990; Anon, 1973; Vlahov et Bacracheva, 1989) e
varia de estudo para estudo. Diferen�as regionais s�o muito
provavelmente relatadas pela avalia��o e uso em modelos em v�rios
pa�ses. A incid�ncia de agranulocitose varia em 1,1 por milh�o,
durante a primeira semana de administra��o (Anon, 1986) e um caso para
cada 3000 usu�rios (Bottiger et Westerholm, 1973). Calculos baseados
em dados levantados, sugerem que o uso da dipirona est� associado a
menos de 7000 casos por ano no mundo todo (Kiatboonsri et Richter,
1989).</p>
<p style="text-align: justify;">Os efeitos cardiovasculares incluem
hipotens�o de moderada at� severa (Hoigne et al, 1986; Sanahuja et al,
1990). Evidencias de hipotens�o com doses orais tamb�m tem sido
descritas (Giovannini et al, 1986; Paeile et Gallardo, 1974).</p>
<p style="text-align: justify;">Efeitos centrais mais significativos s�o
sonol�ncia, astenia e cefal�ia (Lehtonen et al, 1983; Paeile et
Gallardo, 1974).</p>
<p style="text-align: justify;">Efeitos gastrointestinais incluem
n�usea, v�mitos, irrita��o g�strica e xerotomia, que tem sido
relatadas com a administra��o parenteral de dipirona (Marthak et al,
1991; Lehtonen et al, 1983; Paeile et Gallardo, 1974; von Szeged et
Michos, 1986).</p>
<p style="text-align: justify;">Broncoespasmo tamb�m tem sido descrito
em administra�es cont�nuas de dipirona (Arellano et Sacristan, 1990).</p>
<p style="text-align: justify;">Entre as rea�es cut�neas pode ser
encontrado necrose epidermal t�xica, urtic�ria, �rash� cut�neo (Anon,
1973; Arellano et Sacristan, 1990; Pandhi et al, 1984; Pasricha, 1979;
Lehtonen et al, 1983; Saban et al, 1991).</p>
<p style="text-align: justify;">Choque anafil�tico tamb�m pode
acontecer, com uma incid�ncia de 1 caso em 5000 administra�es
(Fosseus et Straughan, 1983; Arellano et Sacristan, 1990; Kiatboonsri
et Richter, 1988).</p>
<p style="text-align: justify;">6.4 � TERATOG�NESE</p>
<p style="text-align: justify;">Em estudo controlado, com administra��o
de dipirona via oral durante a gravidez, mostrou que o desenvolvimento
de tumor de Wilms foi da ordem de 10,9% (com p<0,05). Esse estudo
incluiu 109 casos de tumor de Wilms e 218 controles. A idade
significante dos casos ao tempo do diagn�stico foi de 41,1 meses. As
m�es foram questionadas sobre o uso de medicamentos durante a gravidez
para se determinar a correla��o do desenvolvimento do tumor e o uso de
medicamentos e a dipirona foi a mais utilizada durante a gravidez de
mulheres cujos filhos apresentaram o tumor, possivelmente devido a
facilidade de acesso � droga. Sem dados de estudos prospectivos, o
aumento na indicencia de tumor de Wilms em crian�as expostas �
dipirona n�o pode ser atribuida definitivamente ao f�rmaco, no
entanto, baseado nesses estudos o uso de dipirona durante a gravidez
deve ser evitado (Sharpe et Franco, 1996).</p>
<p style="text-align: justify;">6.5 � INTERA��ES MEDICAMENTOSAS</p>
<p style="text-align: justify;">6.5.1 � ACENOCOUMAROL</p>
<p style="text-align: justify;">N�o foram observados efeitos
significantes nos tempos de coagula��o durante uso concomitante com a
dipirona (Zylber-Katz et al, 1985), por�m sempre � indicado o m�ximo
de cuidado e monitoriza��o do paciente em uso concomitante de dipirona
com anticoagulantes orais, especialmente se houver necessidade da
adi��o de um antiinflamat�rio n�o ester�ide ao tratamento. O efeito
adverso mais comum � o aumento do risco de hemorragias.</p>
<p style="text-align: justify;">6.5.2 � ALENDRONATO</p>
<p style="text-align: justify;">Durante tr�s anos de estudo cl�nico
controlado, envolvendo 2027 pacientes que recebiam antiinflamat�rios
n�o esteroidais, a incid�ncia de efeitos adversos gastrointestinais
foi similar entre os pacientes recebendo alendronato e pacientes
recebendo placebo. No entanto, quando administrado alendronato com
AINEs, e dipirona, a incidencia aumentava, especialmente a irrita��o
g�strica, efeito tamb�m observado com a dipirona (Prod Info Fosamax� ,
1999).</p>
<p style="text-align: justify;">6.5.3 � INIBIDORES DA ECA</p>
<p style="text-align: justify;">� conhecida a intera��o entre os
inibidores da ECA e a dipirona, podendo surgir bradicardia,
frequentemente induzida por hipercalemia (Shionori, 1993). Esse
dist�rbio pode levar a paradas card�acas (Kurata et al, 1999).</p>
<p style="text-align: justify;">6.5.4 � BLOQUEADORES BETA-ADREN�RGICOS</p>
<p style="text-align: justify;">Em uso concomitante de dipirona com
beta-bloqueadores, tem sido reportado aumento na tens�o arterial e
interfer�ncia no controle da press�o sangu�nea (Radack et al, 1987;
Webster et al, 1984; Abate et al, 1990; Chalmers et al, 1984; Durao et
al, 1977; Salvetti et al, 1984; Watkins et al, 1980).</p>
<p style="text-align: justify;">6.5.5 � BLOQUEADORES DE CANAIS DE C�LCIO</p>
<p style="text-align: justify;">O uso de dipirona com bloqueadores de
canais de c�lcio (nifedipina), aumenta o risco de hemorragia
gastrintestinal (Pahor et al, 1996).<br>
</p>
<p style="text-align: justify; font-weight: bold;">7 � EFIC�CIA
COMPARATIVA (ANTONINI et al, 2012)</p>
<p style="text-align: justify;">7.1 � ACETAMINOFENO (Paracetamol)</p>
<p style="text-align: justify;">7.1.1 � FEBRE</p>
<p style="text-align: justify;">Dipirona na dose de 0,5g oral demonstrou
efeitos antipir�ticos mais acentuados que o paracetamol na mesma dose
em pacientes com febre tif�ide e estudo controlado. A redu��o da
temperatura retal foi muito mais significativa com dipirona do que com
paracetamol at� uma ou duas horas ap�s a administra��o. Existe uma
tend�ncia da dipirona para um efeito prolongado, em torno de 6 horas
ou mais (Ajgaonkar et al, 1988).</p>
<p style="text-align: justify;">7.2 � �CIDO ACETILSALIC�LICO (Aspirina)</p>
<p style="text-align: justify;">7.2.1 � FEBRE</p>
<p style="text-align: justify;">Em um estudo pequeno, duplo-cego, o
efeito de 500mg de dipirona �per-�s� foi superior � mesma dose de
�cido acetilsalic�lico no tratamento de febre (Reiner et al, 1984).</p>
<p style="text-align: justify;">7.2.2 � DOR P�S-OPERAT�RIA</p>
<p style="text-align: justify;">O efeito de 500mg de dipirona 500mg
�per-�s� � consideravelmente superior ao do �cido acetilsalic�lico na
mesma dose no tratamento de dor, em estudo controlado (Arellano et
Sacristan, 1990).</p>
<p style="text-align: justify;">7.3 � N-METIL-BUTIL-ESCOPOLAMINA
(Hioscina)</p>
<p style="text-align: justify;">7.3.1 � NA C�LICA RENAL</p>
<p style="text-align: justify;">Em estudo controlado com n=96 pacientes
com c�lica renal, a hioscina em dose 20mg intravenosa foi inefetiva na
remiss�o dos sintomas dolorosos, enquanto a dipirona na dose de 1
grama intravenosa apresentou efeito menor que 2,5 gramas pela mesma
via. 61% dos pacientes tratados com hioscina precisaram da
adminstra��o conjunta de analg�sicos narc�ticos (petidina, nalbufina,
tramadol ou morfina) para controlar a dor, enquanto 17% e 0%,
respectivamente, dos pacientes em uso de dipirona precisaram da adi��o
de analg�sico opi�ide (Lloret et al, 1987).</p>
<p style="text-align: justify;">7.4 � CLONIXINA</p>
<p style="text-align: justify;">7.4.1 � DOR NA P�S-HISTERECTOMIA</p>
<p style="text-align: justify;">Em estudo randomizado, duplo-cego com
n=160 pacientes divididos em 4 grupos de 40 pacientes cada, foi
administrado 30mg em bolus 15 minutos antes da cirurgia e 15mg em
bolus de clonixina ap�s a cirurgia, ou 660mg de dipirona em bolus
antes e 330mg ap�s a histerectomia. 4,4% das pacientes tratadas com
dipirona necessitaram de doses adicionais de dipirina para controlar a
dor no p�s-operat�rio contra 11% das pacientes tratadas com clonixina
(Rodriguez et al, 1993).</p>
<p style="text-align: justify;">7.5 � DEXTROCETOPROFENO</p>
<p style="text-align: justify;">7.5.1 � DOR NO P�S-OPERAT�RIO
ODONTOL�GICO</p>
<p style="text-align: justify;">A dipirona � t�o eficaz quanto do
cetoprofeno em analgesia no p�s-operat�rio odontol�gico (Bagan et al,
1998).</p>
<p style="text-align: justify;">7.6 � DICLOFENACO</p>
<p style="text-align: justify;">7.6.1 � NA C�LICA RENAL</p>
<p style="text-align: justify;">inje��o intravenosa de 2,5 gramas de
dipirona combinada com pitofenona (um espasmol�tico semelhante �
atropina) e fempiverinium (um espasmol�tico hom�logo da papaverina)
tem efeito similar ao diclofenaco na dose 75mg por via intramuscular.
Ou seja, o diclofenaco em monoterapia � mais efetivo que a dipirona em
monoterapia (Sanahuja et al, 1990).</p>
<p style="text-align: justify;">7.6.2 � NA CIATALGIA</p>
<p style="text-align: justify;">No tratamento da ciatalgia (dor do nervo
ci�tico), 2,5 gramas de dipirona intramuscular foi mais efetivo que 75
miligramas de diclofenaco pela mesma via em tratamento controlado,
randomizado, duplo-cego de 260 pacientes que receberam dipirona,
diclofenado ou placebo por via intramuscular. A dipirona foi mais
efetiva que o diclofenaco com in�cio do efeito ap�s uma hora da
aplica��o e prolongando-se por cerca de 48 horas (Babej-Dolle et al,
1994).</p>
<p style="text-align: justify;">7.7 � IBUPROFENO</p>
<p style="text-align: justify;">7.7.1 � NA DOR P�S-CIR�RGICA</p>
<p style="text-align: justify;">Em estudo comparado entre dipirona
magnesiana intramuscular, ibuprofeno e placebo por via oral, a
espectro analg�sico e o tempo de dura��o da a��o entre a dipirona e o
ibuprofeno foram semelhantes e superiores ao placebo (de Miguel Rivero
et al, 1997).</p>
<p style="text-align: justify;">7.8 � INDOMETACINA</p>
<p style="text-align: justify;">7.8.1 � NA C�LICA RENAL</p>
<p style="text-align: justify;">Inje��o intravenosa de 2,5g de dipirona
tem mostrado efeito maior que 50mg de indometacina pela mesma via, no
tratamento da c�lica ureteral em lit�ases (c�lculos) renais (Lehtonen
et al, 1983).</p>
<p style="text-align: justify;">7.9 � KETORALAC</p>
<p style="text-align: justify;">7.9.1 � EM ANALGESIA</p>
<p style="text-align: justify;">Em estudo randomizado, comparando
aplica��o de 30mg de ketorolac por via intramuscular (um AINE derivado
da pirazolona) com 2g de dipirona pela mesma via cada 12 horas em n=60
pacientes com dor de severa � moderada ap�s cirurgia ortop�dica,
encontrou-se uma efic�cia similar entre o ketorolac e a dipirona no
controle da dor nas primeiras 6 horas do p�s-operat�rio. Ap�s os tr�s
dias seguintes, a redu��o da intensidade da dor foi melhor conseguida
com o ketorolac, demonstrando uma efic�cia maior deste analg�sico em
rela��o � dipirona (Fernandez-Sabate et al, 1991).</p>
<p style="text-align: justify;">7.10 � MEPERIDINA (Petidina)</p>
<p style="text-align: justify;">7.10.1 � NA DOR P�S-CIR�RGICA</p>
<p style="text-align: justify;">Dipirona na dose 2,5g intramuscular ou
intravenosa tem sido t�o efetivo quanto 50 ou 100mg de petidina
intravenosa no tratamento da dor p�s-cir�rgica (Patel et al, 1980; Lal
et al, 1973; Arellano et Sacristan, 1990).</p>
<p style="text-align: justify;">7.10.2 � NA C�LICA RENAL</p>
<p style="text-align: justify;">Doses de 2,5g de dipirona intravenosa
tem se mostrado t�o efetivo quanto 50mg de petidina intravenosa no
tratamento da c�lica renal em c�lica ureteral em um estudo randomizado
(Lehtonen et al, 1983).</p>
<p style="text-align: justify;">7.11 � NIMESULIDE</p>
<p style="text-align: justify;">7.11.1 � NA FEBRE</p>
<p style="text-align: justify;">Em um pequeno estudo duplo-cego, 500mg
de dipirona por via oral foi comparada em efic�cia com o nimesulide
(um novo AINE) na dose 100mg pela mesma via, no tratamento da febre
frequentemente produzida por diversos fatores. Ambas as drogas
apresentaram o mesmo escore de efetividade e foram superioras ao �cido
acetilsalic�lico, que tamb�m foi utilizado no estudo, em efeito
(Reiner et al, 1984).</p>
<p style="text-align: justify;">7.11.2 � NA DOR P�S-CIR�RGICA</p>
<p style="text-align: justify;">Em estudo duplo-cego em crian�as com dor
p�s-operat�ria foram utilizados suposit�rios de 100mg de nimesulide e
300mg de dipirona a cada 6 horas e ambas as drogas apresentaram a
mesma efic�cia no tratamento da dor inflamat�rio no p�s-operat�rio das
crian�as (Scharli et al, 1990).</p>
<p style="text-align: justify;">7.12 � PENTAZOCINE</p>
<p style="text-align: justify;">7.12.1 � NA DOR DO P�S-CIR�RGICO
BUCO-MAXILO-FACIL</p>
<p style="text-align: justify;">Administra�es orais de dipirona na dose
300mg e pentazocine na dose 50mg a cada 4 horas mostraram efic�cia
semelhante em tratamento da dor no p�s-cir�rgico de procedimentos
bucais, maxilares e faciais, em estudo duplo-cego. Neste estudo
encontrou-se efeitos adversos maiores causados pelo pentazocine em
rela��o � dipirona (Paeile et Gallardo, 1974).</p>
<p style="text-align: justify;">7.13 � SUPROFENO</p>
<p style="text-align: justify;">7.13.1 � NEURALGIAS CR�NICAS</p>
<p style="text-align: justify;">Suprofeno oral na dose 200mg 3 � 4 vezes
ao dia foi t�o efetivo quanto a dipirona na dose 500mg 3 a 4 vezes ao
dia no tratamento de neuralgias cronicas de moderada a severa em
estudo controlado envolvendo 60 pacientes hospitalizados (von Szeged
et Michos, 1986).</p>
<p style="text-align: justify;">7.14 � TRAMADOL</p>
<p style="text-align: justify;">7.14.1 � NA C�LICA BILIAR AGUDA</p>
<p style="text-align: justify;">Um estudo multic�ntrico e randomizado,
um grupo de 74 pacientes com c�lica aguda severa de ves�cula biliar,
induzida por lit�ase biliar, foram comparados dipirona, 2,5g, hioscina
20mg e tramadol 100mg, todos por via intravenosa. O temp in�cio da
redu��o da dor foi significativamente menor com a dipirona (10,9
minutos), em compara��o com o tramadol (15,8 minutos) e hioscina (25,6
minutos). No grupo tratado com dipirona, 3 pacientes necessitaram de
doses adicionais da droga ap�s 20 minutos, enquanto no grupo da
hioscina 8 pacientes necessitaram de outra dose do f�rmaco e no grupo
tratado com tramadol apenas 1 paciente necessitou de outra dose do
analg�sico (Schmieder et al, 1993).</p>
<p style="text-align: justify;">7.14.2 � NAS ODONTALGIAS</p>
<p style="text-align: justify;">Tramadol na dose 50mg por via oral e
dipirona na dose 100mg pela mesma via foram considerados equipotentes
no tratamento da dor de dente em tratamento experimental de dor
induzida, em estudo controlado envolvendo 10 indiv�duos sadios
(Rohdewald et al, 1988).</p>
<p style="text-align: justify;">7.14.3 � NA DOR P�S-CIR�RGICA</p>
<p style="text-align: justify;">A efic�cia do efeito analg�sico do
tramado (100mg intramuscular) foi comparado com uma associa��o de
dipirona 500mg com difenidramina 12,5mg, drofenina 25mg e benzetilio
2,5mg, para o tratamento da dor p�s-operat�ria em um estudo
controlado, randomizado com 60 pacientes que sofreram cirurgia
abdominal. Ambas as drogas foram administradas a cada 8 horas por 3
dias. A intensidade da dor foi reduzida mais efetivamente com tramadol
ap�s a primeria dose e durante os tr�s dias de tratamento (p<0,05)
e a qualidade do sono dos pacientes foi significativamente melhor com
o tramadol do que com a dipirona associada (p<0,001). Efeitos
adversos apareceram em 3 pacientes do grupo com tramadol e apenas em
um paciente no grupo com dipirona associada (Canepa et al, 1993).</p>
<p style="text-align: justify;"><strong>8 � REFERENCIAS BIBLIOGR�FICAS </strong></p>
<ol>
<li style="text-align: justify;">Abate MA, Layne RD, Neely JL et al. <strong>Effect
of naproxen and sulindac on blood pressure response to atenolol.</strong>
Drug Intell Clin Pharm 1990; 24:810-813.</li>
<li style="text-align: justify;">Abate MA, Neely JL, Layne RD et al. <strong>Interaction
of indomethacin and sulindac with labetolol</strong>. Br J Clin
Pharmacol 1991; 31:363-366.</li>
<li style="text-align: justify;">Abbate R, Gori AM, Pinto S et al. <strong>Cyclooxygenase
and lipoxygenase metabolite synthesis by polymorphonuclear
neutrophils: in vitro effect of dipyrone</strong>.
Prostagl
Leukotr Ess Fatty Acids 1990;<br>
41:89-93.</li>
<li style="text-align: justify;">Agar JW. <strong>Cyclosporine A and
mefenamic acid in a renal transplant patient</strong>. Aust N Z J
Med 1991; 21:784-785.</li>
<li style="text-align: justify;">Ahmad S. <strong>Indomethacin-enalapril
interaction: an alert (letter). </strong>South Med J 1991;
84:411-412.</li>
<li style="text-align: justify;">Ajgaonkar VS, Marathe SN et Virani
AR. <strong>Dipyrone versus paracetamol: a double-blind study in
typhoid fever</strong>. J Int Med Res 1988;<br>
16:225-230.</li>
<li style="text-align: justify;">Ajgaonkar VS et Pinto Pereira LM. <strong>Patient
study of antipyretic drug efficacy</strong>. Curr Ther Res 1985;
33:440-445.</li>
<li style="text-align: justify;">Altman RD, Perez GO et Sfakianakis
GN. <strong>Interaction of cyclosporine A and nonsteroidal
anti-inflammatory drugs on renal function in patients with
rheumatoid arthritis</strong>. Am J Med 1992; 93:396-402.</li>
<li style="text-align: justify;">Anon. <strong>Comparative study of
the efficacy of dipyrone, diclofenac sodium and pethidine in acute
renal colic</strong>. Eur J Clin Pharmacol 1991; 40:543-546.</li>
<li style="text-align: justify;">Anon. <strong>Dipyrone and
aminopyrine � for relief of fever</strong>. Med Lett Drugs Ther
1973; 15:4.</li>
<li style="text-align: justify;">Anon. <strong>Dipyrone as a cause of
drug rashes: an epidemiologic study</strong>. A report from the
Boston Collaborative Drug Surveillance Program. Int J Epidemiol
1973a; 2:167-170.</li>
<li style="text-align: justify;">Anon. <strong>Reports prompt new
warnings on LMW heparin, heparinoids</strong>. Am J Health Syst
Pharm 1998; 55:210.</li>
<li style="text-align: justify;">Anon. <strong>Risks of
agranulocytosis and aplastic anemia: a first report of their
relation to drug use with special reference to analgesics</strong>.
JAMA 1986; 256:1749-1757.</li>
<li style="text-align: justify;">ANTONINI, V, MARAMA, N, SERATICUK, J.
C. <strong>Anu�rio Estat�stico do Servi�o de Farm�cia Hospitalar �
1999. </strong>Curitiba : Servi�o de Farm�cia Hospitalar do
HC-UFPR, 2000.</li>
<li style="text-align: justify;">ANTONINI, V.; TAMBARA, E.; BAVIERA,
M. M.; SILVEIRA, C. R.; SOUZA, E. D. Estudo da Farmacoterapia da Dor
em Pacientes P�s-cir�rgicos do Hospital de Cl�nicas da Universidade
Federal do Paran�. <strong>Infarma</strong>, p. 88�95, jun. 2013.
Bras�lia. Dispon�vel em:
<http://revistas.cff.org.br/seer/ojs-2.3.7/index.php/infarma/article/view/452>.
</li>
<li style="text-align: justify;">Arellano F et Sacristan J�. <strong>Metamizole:
reassessment of its therapeutic role</strong>. Eur J Clin
Pharmacol 1990; 38:617-619.</li>
<li style="text-align: justify;">Babej-Dolle R, Freytag S, Eckmeyer J
et al. <strong>Parenteral dipyrone versus diclofenac and placebo in
patients with acute lumbago or sciatic pain: randomized
observer-blind multicenter study</strong>. Int J Clin Pharmacol
Ther Toxicol 1994; 32:204-209.</li>
<li style="text-align: justify;">Bagan JV, Arranz JSL, Valencia E et
al. <strong>Clinical comparison of dexketoprofen trometamol and
dipyrone in postoperative dental pain</strong>. JClin Pharmacol
1998; 38:55S-64S.</li>
<li style="text-align: justify;">Bagan JV, Lopez Arranz S, Valencia E
et al. <strong>Clinical comparison of dexketoprofen trometamol and
dipyrone in postoperative dental pain</strong>. JClin Pharmacol
1998; 38(suppl):55S-64S.</li>
<li style="text-align: justify;">Bahrt KM, Korman LY et Nashel DJ. <strong>Significance
of a positive test for occult blood in stools of patients taking
anti-inflammatory drugs</strong>. Arch Intern Med 1984;
144:2165-2166.</li>
<li style="text-align: justify;">Bloch B, Smythe E et Weeks R. <strong>Analgesics
for pain relief after gynaecological surgery</strong>. S Afr Med J
1985; 67:325-329.</li>
<li style="text-align: justify;">Bottiger LE et Westerholm B. <strong>Drug-induced
blood dyscrasias in Sweden</strong>. Br Med J 1973; 3:339-343.</li>
<li style="text-align: justify;">Branthwaite JP et Nicholls A. <strong>Cyclosporine
and diclofenac interaction in rheumatoid arthritis </strong>(letter).
Lancet
1991; 337:252.</li>
<li style="text-align: justify;">Brenner S, Bialy-Golan A et Crost N.
<strong>Dipyrone in the induction of pemphigus</strong>. J Amer Acad
Dermatol 1997; 36:488- 490.</li>
<li style="text-align: justify;">Brune K. <strong>The pharmacological
profile of non-opioid (OTC) analgesics: aspirin, paracetamol
(acetaminophen), ibuprofen, and phenazones</strong>. Agents
Actions 1988; 25(suppl):9-19.</li>
<li style="text-align: justify;">Canepa G, DiSomma C, Ghia M et al. <strong>Post-operative
analgesia with tramadol: a controlled clinical study compared with
analgesic combination</strong>. Int J Clin Pharm Res 1993;
13:43-51.</li>
<li style="text-align: justify;">Cassano WF. <strong>Serious
methotrexate toxicity caused by interaction with ibuprofen </strong>(letter).
Am
J Pediatr Hematol Oncol 1989; 11:481-482.</li>
<li style="text-align: justify;">Chalmers JP, West MJ, Wing LM et al.
<strong>Effects of indomethacin, sulindac, naproxen, aspirin, and
paracetamol in treated hypertensive patients</strong>. Clin Exp
Hypertens 1984; 6:1077-1093.</li>
<li style="text-align: justify;">Chennavasin P, Seiwell R et Brater
DC. <strong>Pharmacokinetic-dynamic analysis of the
indomethacin-furosemide interaction in man</strong>. J Pharmacol
Exp Ther 1980; 215:77-81.</li>
<li style="text-align: justify;">Chlud K et Kaik VB. <strong>Clinical
studies of the interaction between tolmetin and glibenclamide</strong>.
Int J Clin Pharmacol 1977; 15:409-410.</li>
<li style="text-align: justify;">Cohen O, Zylber-Katz E, Caraco Y et
al. <strong>Cerebrospinal fluid and plasma concentrations of
dipyrone metabolites after a single oral dose of dipyrone</strong>.
Eur J Clin Pharmacol 1998; 54:549-553.</li>
<li style="text-align: justify;">Collins CL, DeTullio PL, Berardi RR
et al. <strong>Comparison of home occult blood tests and
interaction of tests with ibuprofen</strong>. Clin Pharm 1989;
8:501-504.</li>
<li style="text-align: justify;">Constantopoulos A. <strong>Colitis
induced by interaction of cyclosporine A and non-steroidal
anti-inflammatory drugs</strong>. Pediatr Intl 1999; 41:184-186.</li>
<li style="text-align: justify;">CRUNFLI, F.; VILELA, F. C.;
GIUSTI-PAIVA, A. Cannabinoid CB1 receptors mediate the effects of
dipyrone. <strong>Clinical and Experimental Pharmacology and
Physiology</strong>, v. 42, n. 3, p. 246�255, 2015.</li>
<li style="text-align: justify;">Daly H, Boyle J, Roberts C et al: <strong>Interaction
between methotrexate and non-steroidal anti-inflammatory drugs</strong>.
Lancet 1986; 1:559.</li>
<li style="text-align: justify;">Das UN: <strong>Modification of
anti-hypertensive action of verapamil by inhibition of endogenous
prostaglandin synthesis</strong>. Prostaglandins Leukot Med 1982;
9:167-169.</li>
<li style="text-align: justify;">Davis A, Day RO et Begg EJ: <strong>Interactions
between non-steroidal anti-inflammatory drugs and
antihypertensives and diuretics</strong>. Aust N Z J Med 1986;
16:537-546.</li>
<li style="text-align: justify;">Day RO, Geisslinger G, Paull P et al:
<strong>The effect of tenoxicam on tolbutamide pharmacokinetics and
glucose concentrations in healthy volunteers</strong>. Int J Clin
Pharmacol Ther 1995; 33:308-310.</li>
<li style="text-align: justify;">de Miguel Rivero C, Araujo CG, Sousa
MM et al: <strong>Comparative efficacy of oral ibuprofen-arginine,
intramuscular magnetic dipyrone and placebo in patients with
postoperative pain following total hip replacement</strong>. Clin
Drug Invest 1997; 14:276-285.</li>
<li style="text-align: justify;">Deray G, Le Hoang P, Aupetit B et al:
<strong>Enhancement of cyclosporine A nephrotoxicity by diclofenac </strong>(letter).
Clin Nephrol 1987; 27:213-214.</li>
<li style="text-align: justify;">Dixey JJ, Noormohamed FH, Lant AF et
al: <strong>The effects of naproxen and sulindac on renal function
and their interaction with hydrochlorothiazide and piretanide in
man</strong>. Br J Clin Pharmacol 1987; 23:55-63.</li>
<li style="text-align: justify;">Dupuis LL, Shore A, Silverman ED et
al: <strong>Methotrexate-nonsteroidal antiinflammatory drug
interaction in children with arthritis. </strong>J Rheumatol
1990; 17:1469-1473.</li>
<li style="text-align: justify;">Durao V, Prata MM et Goncalves LM: <strong>Modification
of antihypertensive effect of beta-adrenoreceptor blocking agents
by inhibition of endogenous prostaglandin synthesis</strong>.
Lancet 1977; 2:1005-1007.</li>
<li style="text-align: justify;">Ebel DL, Rhymer AR, Stahl E et al: <strong>Effect
of Clinoril (sulindac, MSD), piroxicam and placebo on the
hypotensive effect or propranolol in patients with mild to
moderate essential hypertension</strong>. Scand J Rheumatol 1986;
62(suppl):41S-49S.</li>
<li style="text-align: justify;">Fairley KF, Woo KT, Birch DF et al: <strong>Triamterene-induced
crystalluria and cylinduria: clinical and experimental studies</strong>.
Clin Nephrol 1986; 26:169-173.</li>
<li style="text-align: justify;">Fauno P, Petersen KD et Husted SE: <strong>Increased
blood loss after preoperative NSAID. </strong>Acta Orthop Scand
1993; 64:522-524.</li>
<li style="text-align: justify;">Favre L, Glasson P, Riondel A et al:
<strong>Interaction of diuretics and non-steroidal anti-inflammatory
drugs in man</strong>. Clin Sci 1983; 64:407-415.</li>
<li style="text-align: justify;">Favre L, Glasson P et Vallotton MB: <strong>Reversible
acute renal failure from combined triamterene and indomethacin</strong>.
Ann Intern Med 1982;<br>
96:317-320. Fernandez-Sabate A, Roca-Burniol J, Roca-Barbera A et
al: <strong>Ketorolac, a new nonopioid analgesic, in a single-blind
trial versus metamizole in orthopedic surgery pain. </strong>Curr
Ther Res 1991; 49:1016-1024.</li>
<li style="text-align: justify;">Fleming JL, Ahlquist DA, McGill DB et
al: <strong>Influence of aspirin and ethanol on fecal blood levels
as determined by using the HemoQuant assay</strong>. Mayo Clin
Proc 1987; 62:159-163.</li>
<li style="text-align: justify;">Flusser D, Zylber-Katz E, Granit L et
al: <strong>Influence of food on the pharmacokinetics of dipyrone.
</strong>Eur J Clin Pharmacol 1988; 34:105-107.</li>
<li style="text-align: justify;">Fosseus CG et Straughan H: <strong>Sudden
death due to intravenous avapyrazone and dipyrone</strong>. S Afr
Med J 1983; 64:81.</li>
<li style="text-align: justify;">Frolich JC, Rupp WA, Zapf RM et al: <strong>The
effects of metamizol on prostaglandin synthesis in man</strong>.
Agents Actions Suppl 1986; 19:155-166</li>
<li style="text-align: justify;">Furst DE: <strong>Clinically
important interactions of nonsteroidal antiinflammatory drugs with
other medications</strong>. J Rheumatol Suppl 1988; 17:58-62.</li>
<li style="text-align: justify;">Furst DE, Herman RA, Koehnke R et al:
<strong>Effect of aspirin and sulindac on methotrexate clearance. </strong>J
Pharm Sci 1990; 79:782-786.</li>
<li style="text-align: justify;">Giovannini M, Longhi R, Besana R et
al: <strong>Clinical experience and results of treatment with
suprofen in pediatrics. 5th communication: a single-blind study on
antipyretic effect and tolerability of suprofen syrup versus
metamizole drops in pediatric patients</strong>.
Arzneimittelforschung 1986; 36:959-964.</li>
<li style="text-align: justify;">Gladtke E: <strong>Use of
antipyretic analgesics in the pediatric patient</strong>. Am J Med
1983; Symposium Nov. 14:121-126.</li>
<li style="text-align: justify;">Greer IA, Gibson JL, Young A et al: <strong>Effect
of ketorolac and low-molecular-weight heparing individually and in
combination on haemostasis</strong>. Blood Coagul Fibrinolysis
1999; 10:367-373.</li>
<li style="text-align: justify;">Greer IA, Gibson JL, Young A et al: <strong>Effect
of ketorolac and low-molecular-weight heparin individually and in
combination on haemostasis</strong>. Blood Coagul Fibrinolysis
1999; 10:367-373.</li>
<li style="text-align: justify;">Hardy BG, Bartle WR, Myers M et al: <strong>Effect
of indomethacin on the pharmacokinetics and pharmacodynamics of
felodipine</strong>. Br J Clin Pharmacol 1986; 26:719-720.</li>
<li style="text-align: justify;">Hargis JB, LaRussa VF, Redmond J et
al: <strong>Agranulocytosis associated with �Mexican aspirin�
(dipyrone): evidence for an autoimmune mechanism affecting
multipotential hematopoietic progenitors</strong>. Am J Hematol
1989; 31:213-215.</li>
<li style="text-align: justify;">Harris KP, Jenkins D et Walls J: <strong>Nonsteroidal
antiinflammatory drugs and cyclosporine: a potentially serious
adverse interaction</strong>. Transplantation 1988; 46:598-599.</li>
<li style="text-align: justify;">Harvey PJ, Wing LM, Beilby J et al: <strong>Effect
of indomethacin on blood pressure control during treatment with
nitrendipine</strong>. Blood Press 1995; 4:307-312.</li>
<li style="text-align: justify;">Heerdink ER, Leufkens HG, Herings RMC
et al: <strong>NSAIDs associated with increased risk of congestive
heart failure in elderly patients taking diuretics</strong>. Arch
Intern Med 1998; 158:1108-1112.</li>
<li style="text-align: justify;">Heinemeyer G, Gramm HJ, Roots I et
al: <strong>The kinetics of metamizol and its metabolites in
critical-care patients with acute renal dysfunction</strong>. Eur
J Clin Pharmacol 1993; 45:445-450.</li>
<li style="text-align: justify;">Hempel V: <strong>Pyrazolones in the
treatment of postoperative pain. </strong>Agents Actions 1986;
19(suppl):331-337.</li>
<li style="text-align: justify;">Hoigne R, Zoppi M, Sollberger J et
al: <strong>Fall in systolic blood pressure due to metamizol
(dipyrone, noramidopyrine, novaminsulfone)</strong>. Agents
Actions 1986; 19(auppl):189-195.</li>
<li style="text-align: justify;">Houston MC, Weir M, Gray J et al: <strong>The
effects of nonsteroidal anti-inflammatory drugs on blood pressures
of patients with hypertension controlled by verapamil</strong>.
Arch Intern Med 1995; 155:1049-1054.</li>
<li style="text-align: justify;">Huguley CH:<strong> Agranulocytosis
induced by dipyrone, a hazardous antipyretic and analgesic</strong>.
JAMA 1964; 189:938-941.</li>
<li style="text-align: justify;">KATZUNG, B.G. <strong>Basic and
Clinical Pharmacology</strong>. 14� Ed. San Francisco CA : Mc Graw
Hill, 2017.</li>
<li style="text-align: justify;">Kiatboonsri P et Richter J: <strong>Dipyrone
trials in Thailand </strong>(letter). Lancet 1989; 2:107.</li>
<li style="text-align: justify;">Kiatboonsri P et Richter J: <strong>Unethical
trials of dipyrone in Thailand </strong>(letter). Lancet 1988;
2:1491.</li>
<li style="text-align: justify;">Kirchner KA: <strong>Role of
antidiuretic hormone in the attenuated furosemide response
observed during indomethacin administration</strong>. J Lab Clin
Med 1988; 111:237-243.</li>
<li style="text-align: justify;">Klassen DK, Jane LH, Young DY et al:
<strong>Assessment of blood pressure during naproxen therapy in
hypertensive patients treated with nicardipine</strong>. Am J
Hypertens 1995; 8:146-153.</li>
<li style="text-align: justify;">Koopmans PP, Kateman WG, Tan Y et al:
<strong>Effects of indomethacin and sulindac on hydrochlorothiazide
kinetics</strong>. Clin Pharmacol Ther 1985; 37:625-628.</li>
<li style="text-align: justify;">Koopmans PP, Thien T et Gribnau FWJ:
<strong>The influence of ibuprofen, diclofenac and sulindac on the
blood pressure lowering effect of hydrochlorothiazide</strong>.
Eur J Clin Pharmacol 1987; 31:553-557.</li>
<li style="text-align: justify;">Koopmans PP, Thien T, Thomas CM et
al: <strong>The effects of sulindac and indomethacin on the
anti-hypertensive and diuretic action of hydrochlorothiazide in
patients with mild to moderate essential hypertension</strong>. Br
J Clin Pharmacol 1986; 21:417-423.</li>
<li style="text-align: justify;">Kovarik JM, Kurki P, Mueller E et al:
<strong>Diclofenac combined with cyclosporine in treatment
refractory rheumatoid arthritis: longitudinal safety assessment
and evidence of a pharmacokinetic/dynamic interaction</strong>. J
Rheumatol 1996; 23:2033-2038.</li>
<li style="text-align: justify;">Kulkarni RD, Bakhle DS, et Pinto
Pereira LM: <strong>Objective evaluation of antipyretic activity in
human volunteers</strong>. IRCS Med Sci 1985; 13;148-149.</li>
<li style="text-align: justify;">Kurata C, Uehara A, Sugi T et al: <strong>Syncope
caused by nonsteroidal anti-inflammatory drugs and
angiotensin-converting enzyme inhibitors</strong>. Jpn Circ J
1999; 63:1002-1003.</li>
<li style="text-align: justify;">Lal A, Pandey K, Chandra P et al: <strong>Dipyrone
for treatment of post-operative pain. </strong>Anaesthesia 1973;
28:43-47.</li>
<li style="text-align: justify;">Lay WH: <strong>Drug-induced
haemolytic reactions to antibodies against the
erythrocyte/dipyrone complex</strong>. Vox Sang 1966; 11:601-610.</li>
<li style="text-align: justify;">Lehtonen T, Kellokumpu I, Permi J et
al: <strong>Intravenous indomethacin in the treatment of ureteric
colic</strong>. Ann Clin Res 1983; 15:197-199.</li>
<li style="text-align: justify;">Levy M, Leibowich I, Zylber-Katz E et
al: <strong>Impairment of the metabolism of dipyrone in
asymptomatic carriers of the hepatitis B virus</strong>. Clin
Pharmacol Ther 1997; 62:6-14.</li>
<li style="text-align: justify;">Levy M: <strong>Pharmacokinetics of
metamizol metabolites</strong>. Agents Actions 1986;
19(suppl):199-204.</li>
<li style="text-align: justify;">Levy M, Zylber-Katz E et Rosenkranz
B: <strong>Clinical pharmacokinetics of dipyrone and its
metabolites</strong>. Clin Pharmacokinet 1995; 28(3):216-234.</li>
<li style="text-align: justify;">Lloret J, Munoz J, Mommany J et al: <strong>Treatment
of renal colic with dipyrone</strong>. Curr Ther Res 1987;
42:1119-1128.</li>
<li style="text-align: justify;">Maiche AG: <strong>Acute renal
failure due to concomitant action of methotrexate and indomethacin
</strong>(letter). Lancet 1986; 1:1390</li>
<li style="text-align: justify;">Marthak KV, Gokarn AM, Rao AV et al:
<strong>A multi-centre comparative study of diclofenac sodium and a
dipyrone/spasmolytic combination, and a single-centre comparative
study of diclofenac sodium and pethidine in renal colic patients
in India</strong>. Curr Med Res Opin 1991; 12:366-373.</li>
<li style="text-align: justify;">Marthak KV, Gokarn AM, Rao AV et al:
<strong>A multi-centre comparative study of diclofenac sodium and a
dipyrone/spasmolytic combination, and single-centre comparative
study of diclofenac sodium and pethidine in renal colic patients
in India</strong>. Curr Med Res Opin 1991; 12:366-373.</li>
<li style="text-align: justify;">Mathews A et Baillie FR: <strong>Acute
renal failure and hyperkalaemia associated with triamterene and
indomethacin</strong>. Vet Hum Toxicol 1986; 28:224-225.</li>
<li style="text-align: justify;">McCarthy JT, Torres VE, Romero JC et
al: <strong>Acute intrinsic renal failure induced by indomethacin:
role of prostaglandin synthetase inhibition</strong>. Mayo Clin
Proc 1982; 57:289-296.</li>
<li style="text-align: justify;"><strong>MICROMEDEX, Healthcare Series
v. 116</strong>. Englewood, Colorado � USA : sept, 2000. (Banco de
dados em farmacologia e terapeutica).</li>
<li style="text-align: justify;">Mills EH, Whitworth JA, Andrews J et
al: <strong>Non-steroidal anti-inflammatory drugs and blood
pressure</strong>. Aust N Z J Med 1982; 12:478-482.</li>
<li style="text-align: justify;">Minuz P, Pancera P, Ribul M et al: <strong>Amlodipine
and haemodynamic effects of cyclo-oxygenase inhibition</strong>.
Br J Clin Pharmacol 1995; 39:45-50.</li>
<li style="text-align: justify;">Morgan T et Anderson A: <strong>Interaction
of indomethacin with felodipine and enalapril</strong>. J
Hypertens 1993; 11(suppl 5):338S-339S.</li>
<li style="text-align: justify;">Mork NL et Robertson RP: <strong>Effects
of nonsteroidal antiinflammatory drugs in conventional dosage on
glucose homeostasis in patients with diabetes</strong>. West J Med
1983; 139:46-49.</li>
<li style="text-align: justify;">Morrison PJ, Rogers HJ, Spector RG et
al: <strong>Effect of pirprofen on glibenclamide kinetics and
response</strong>. Br J Clin Pharmacol 1982; 14:123-126.</li>
<li style="text-align: justify;">Mor R, Pitlik S et Rosenfeld JB: <strong>Indomethacin
and Moduretic-induced hyperkalemia</strong>. Isr J Med Sci 1983;
19:535-537.</li>
<li style="text-align: justify;">Muck W, Heine PR, Schmage N et al: <strong>Steady-state
pharmacokinetics of nimodipine during chronic administration of
indometacin in elderly healthy volunteers. </strong>Arzneimittelforschung
1995;
45:460-462.</li>
<li style="text-align: justify;">Muck W, Heine PR, Schmage N et al: <strong>Steady-state
pharmacokinetics of nimodipine during chronic administration of
indomethacin in elderly healthy volunteers</strong>.
Arzneimittelforschung 1995; 45:460-462.</li>
<li style="text-align: justify;">Nies AS, Gal J, Fadul S et al: <strong>Indomethacin-furosemide
interaction: the importance of renal blood flow</strong>. J
Pharmacol Exp Ther 1983; 226:27-32.</li>
<li style="text-align: justify;">Nies AS: <strong>Renal effects of
nonsteroidal anti-inflammatory drugs</strong>. Agents Actions
1988; 24(suppl):95-106.</li>
<li style="text-align: justify;">Norfleet RG: <strong>1,300 mg of
aspirin daily does not cause positive fecal hemoccult tests</strong>.
J Clin Gastroenterol 1983; 5:123-125.</li>
<li style="text-align: justify;">Okonek S: <strong>Intoxication with
pyrazolones</strong>. Br J Clin Pharmacol 1980; 10:385S-390S.</li>
<li style="text-align: justify;">Okonek S et Reinecke HJ: <strong>Acute
toxicity of pyrazolones</strong>. Am J Med 1983; Symposium Nov
14:94-98.</li>
<li style="text-align: justify;">ORTU�O, F. M.; VALENZUELA, O.; ROJAS,
F.; et al. Optimizing multiple sequence alignments using a genetic
algorithm based on three objectives: structural information,
non-gaps percentage and totally conserved columns. <strong>Bioinformatics
(Oxford, England)</strong>, v. 29, n. 17, p. 2112�21, 2013.
Dispon�vel em: <http://www.ncbi.nlm.nih.gov/pubmed/23793754>.
Acesso em: 11/8/2014.</li>
<li style="text-align: justify;">Paeile C et Gallardo F: <strong>Analgesic
activity of pentazocine and dipyrone in ambulatory oral surgery
patients</strong>. J Oral Surg 1974; 32:191-194.</li>
<li style="text-align: justify;">Pahor M, Gurainik JM, Furberg CD et
al: <strong>Risk of gastrointestinal haemorrhage with calcium
antagonists in hypertensive persons over 67 years old</strong>.
Lancet 1996; 347:1061-1065.</li>
<li style="text-align: justify;">Pancera P, Arosio E, Minuz P et al: <strong>Changes
in peripheral hemodynamics and vasodilating prostaglandins after
high-dose short-term ibuprofen in chronically treated hypertensive
patients</strong>. Prostaglandins Leukot Essent Fatty Acids 1996;
54:217-222.</li>
<li style="text-align: justify;">Pandhi RK, Kumar AS, Satish DA et al:
<strong>Fixed drug eruptions on male genitalia: clinical and
etiologic study</strong>. Sex Transm Dis 1984; 11:164-166.</li>
<li style="text-align: justify;">Pasricha JS: <strong>Drugs causing
fixed eruptions</strong>. Br J Dermatol 1979; 100:183-185.</li>
<li style="text-align: justify;">Patel CV, Koppikar MG, Patel MS et
al: <strong>Management of pain after abdominal surgery: dipyrone
compared with pethidine</strong>. Br J Clin Pharmacol 1980;
10:351S-354S.</li>
<li style="text-align: justify;">Pedrinelli R, Magagna A, Arzilli F et
al: <strong>Influence of indomethacin on the natriuretic and
renal-stimulating effect of bumetanide in essential hypertension</strong>.
Clin Pharmacol Ther 1980; 28:722-730.</li>
<li style="text-align: justify;">Peterson MS et al: <strong>Differential
effects of naproxen and diclofenac on verapamil pharmacokinetics</strong>.
Clin Pharmacol Ther 1991; 49:129.</li>
<li style="text-align: justify;">Pilotto A, Leandro G, Franceschi M et
al: <strong>Antagonism to calcium antagonists. </strong>Lancet
1996; 347:1761-1762.</li>
<li style="text-align: justify;">Polonia J, Boaventura I, Gama G et
al: <strong>Influence of non-steroidal anti-inflammatory drugs on
renal function and 24h ambulatory blood pressure-reducing effects
of enalapril and nifedipine gastrointestinal therapeutic system in
hypertensive patients</strong>. J Hypertens 1995; 13:925-931.</li>
<li style="text-align: justify;">Pond SM, Birkett DJ et Wade DN: <strong>Mechanisms
of inhibition of tolbutamide metabolism: phenylbutazone,
oxyphenbutazone, sulfaphenazole</strong>. Clin Pharmacol Ther
1977; 22:573-579.</li>
<li style="text-align: justify;">Pond SM, Birkett DJ et Wade DN. <strong>Mechanisms
of inhibition of tolbutamide metabolism: phenylbutazone,
oxyphenbutazone, sulfaphenazole</strong>. Clin Pharmacol Ther
1977; 22(5 pt 1):573-579.</li>
<li style="text-align: justify;">Porterfield WR et Wu CL. <strong>Epidural
hematoma in an ambulatory surgical patient</strong>. J Clin Anesth
1997; 9:74-76.</li>
<li style="text-align: justify;">Pritchard G, Lyons D, Webster J et
al. <strong>Do trandolapril and indomethacin influence renal
function and renal functional reserve in hypertensive patients. </strong>Br
J
Clin
Pharmacol 1997; 44:145-149.</li>
<li style="text-align: justify;"><strong>Product Information</strong>:
Coumadin(R), warfarin sodium. DuPont Pharma, Wilmington, DE, 1999.</li>
<li style="text-align: justify;"><strong>Product Information</strong>:
Floxin(R), ofloxacin. Ortho Pharmaceutical Corporation, Raritan, NJ,
1995.</li>
<li style="text-align: justify;"><strong>Product Information</strong>:
Fosamax(R), alendronate sodium. Merck et Co., Inc., West Point, PA,
1999.</li>
<li style="text-align: justify;"><strong>Product Information</strong>.
Integrilin(R), eptifibatide. Key Pharmaceuticals, Inc., Kenilworth,
NJ, 1999.</li>
<li style="text-align: justify;"><strong>Product Information</strong>.
Lovenox(R), enoxaparin sodium. Rhone-Poulenc Rorer Pharmaceuticals
Inc., Collegeville, PA, 1999.</li>
<li style="text-align: justify;"><strong>Product Information</strong>.
Naprelan(TM), naproxen sodium. Wyeth-Ayerst Laboratories,
Philadelphia, PA, 1996.</li>
<li style="text-align: justify;"><strong>Product Information</strong>.
Orgaran(TM), danaparoid sodium injection. Organan Inc., West Orange,
NJ, 1998.</li>
<li style="text-align: justify;"><strong>Product Information</strong>.
Toradol(R), ketorolac tromethamine. Roche Laboratories Inc., Nutley,
NJ, 1996.</li>
<li style="text-align: justify;"><strong>Product Information</strong>.
Voltaren(R), diclofenac sodium. Novartis Pharmaceuticals
Corporation, East Hanover, NJ, 1996.</li>
<li style="text-align: justify;">Pye G, Ballantyne KC, Armitage NC et
al. <strong>Influence of non-steroidal anti-inflammatory drugs on
the outcome of faecal occult blood tests in screening for
colorectal cancer</strong>. Br Med J 1987; 294:1510-1511.</li>
<li style="text-align: justify;">Radack KL, Deck CC et Bloomfield SS.
<strong>Ibuprofen interferes with the efficacy of antihypertensive
drugs. A randomized, double-blind, placebo-controlled trial of
ibuprofen compared with acetaminophen</strong>. Ann Intern Med
1987; 107:628-635.</li>
<li style="text-align: justify;">Ragheb M, Ban TA, Buchanan D et al. <strong>Interaction
of indomethacin and ibuprofen with lithium in manic patients under
a steady-state lithium level. </strong>J Clin Psychiatry 1980;
41:397-398.</li>
<li style="text-align: justify;">RANG, H.P, DALE, M. M., RITTER, J. M.
<strong>FARMACOLOGIA</strong>. 8� ed. S�o Paulo: Elsevier, 2016.</li>
<li style="text-align: justify;">Rapeport WG, Grimwood VC, Hosie J et
al: <strong>The effect of tenidap on the anti-hypertensive efficacy
of ACE inhibitors in patients treated for mild to moderate
hypertension</strong>. Br J Clin Pharmacol 1995;
39(suppl):57S-61S.</li>
<li style="text-align: justify;">Rapeport WG, Grimwood VC, Korlipara K
et al. <strong>The effect of tenidap on the anti-hypertensive
efficacy of thiazide diuretics in patients treated for mild to
moderate hypertension</strong>. Br J Clin Pharmacol 1995;
39(suppl1):51S-55S.</li>
<li style="text-align: justify;">Ravic M, Johnston A et Turner P. <strong>Clinical
pharmacological studies of some possible interactions of
lornoxicam with other drugs</strong>. Postgrad Med J 1990;
66(suppl 4):S30-S34.</li>
<li style="text-align: justify;">Reiner M, Massera E et Magni E. <strong>Nimesulide
in the treatment of fever: a double-blind crossover clinical trial</strong>.
J Int Med Res 1984; 12:102-107.</li>
<li style="text-align: justify;">Reynolds JEF (ed). <strong>Martindale:
The Extra Pharmacopoeia </strong>(electronic version).
Micromedex, Inc, Denver, CO, 1992.</li>
<li style="text-align: justify;">Ribera A, Monasterio J, Acebedo G et
al. <strong>Dipyrone-induced immune haemolytic anaemia</strong>.
Vox Sang 1981; 41:32-35.</li>
<li style="text-align: justify;">Rodriguez M, Barutell C, Rull M et
al. <strong>Efficacy and tolerance of oral dipyrone versus oral
morphine for cancer pain</strong>. Eur J Cancer 1994;
30A(5):584-587.</li>
<li style="text-align: justify;">Rodriguez MJ, de la Torre MR,
Perez-Iraola P et al. <strong>Comparative study of tramadol versus
NSAIDs as intravenous continuous infusion for managing
postoperative pain</strong>. Curr Ther Res 1993; 54:375-383.</li>
<li style="text-align: justify;">Rohdewald P, Granitzki HW et
Neddermann E. <strong>Comparison of the analgesic efficacy of
metamizole and tramadol in experimental pain</strong>.
Pharmacology 1988; 37:209-217.</li>
<li style="text-align: justify;">Roots I, Kampf D, Heinemeyer G et al.
<strong>Changes in metamizol kinetics and metabolism during chronic
and acute renal failure as compared to healthy volunteers</strong>.
Arch Pharmacol 1985; 330(suppl):R81.</li>
<li style="text-align: justify;">Ryan JR, Jain AK, McMahon G et al. <strong>On
the question of an interaction between sulindac and tolbutamide in
the control of diabetes</strong>. Clin Pharmacol Ther 1977;
21:231-233.</li>
<li style="text-align: justify;">Saban J, Pais JR, Rodriguez JL et al.
<strong>Sjogren-like pluriglandular exocrine insufficiency after
drug-induced toxic epidermal necrolysis</strong>. Postgrad Med J
1991; 67:195-197.</li>
<li style="text-align: justify;">Sadusk JF. <strong>The relationship
of the Food and Drug Administration to the practice of medicine
and the aminopyrine-dipyrone problem</strong>. South Med J 1965;
58:1508-1512.</li>
<li style="text-align: justify;">Salvetti A, Arzilli F, Pedrinelli R
et al. <strong>Interaction between oxprenolol and indomethacin on
blood pressure in essential hypertensive patients</strong>. Eur J
Clin Pharmacol 1982; 22:197-201.</li>
<li style="text-align: justify;">Salvetti A, Pedrinelli R, Alberici P
et al. <strong>The influence of indomethacin and sulindac on some
pharmacological actions of atenolol in hypertensive patients</strong>.
Br J Clin Pharmacol 1984; 17(suppl):108S-111S.</li>
<li style="text-align: justify;">Sanahuja J, Corbera G, Garau J et al.
<strong>Intramuscular diclofenac sodium versus intravenous Baralgin
in the treatment of renal colic</strong>. DICP 1990; 24:361-364.</li>
<li style="text-align: justify;">Sanahuja J, Corbera G, Garau J et al.
<strong>Intramuscular diclofenac sodium versus intravenous Baralgin
in the treatment of renal colic</strong>. DICP Ann Pharmacother
1990; 24:361-364.</li>
<li style="text-align: justify;">Sansone G, Reali S, Sansone R et al.
<strong>Acute hemolytic anemia induced by a pyrazolonic drug in a
child with glucose-6-phosphate dehydrogenase deficiency</strong>.
Acta Haematol 1984; 72:285-287.</li>
<li style="text-align: justify;">SANTOS, G. G.; DIAS, E. V.; TEIXEIRA,
J. M.; et al. The analgesic effect of dipyrone in peripheral tissue
involves two different mechanisms: neuronal K(ATP) channel opening
and CB(1) receptor activation. <strong>European journal of
pharmacology</strong>, v. 741, p. 124�31, 2014. Dispon�vel em:
<http://www.ncbi.nlm.nih.gov/pubmed/25058903>.</li>
<li style="text-align: justify;">Scharli AF, Brulhart K et Monti T. <strong>Pharmacokinetics
and therapeutic study with nimesulide suppositories in children
with post-operative pain and inflammation</strong>. J Int Med Res
1990; 18:315-321.</li>
<li style="text-align: justify;">Schmieder G, Stankov G, Zerle G et
al. <strong>Observer-blind study with metamizole versus tramadol
and butylscopolamine in acute biliary colic pain</strong>.
Arzneimittelforschung 1993; 43:1216-1221.</li>
<li style="text-align: justify;">Schulz E, Koch K et Schmidt FH. <strong>Ursachen
der potenzierung der hypoglykamischen wirkung von
sulfonylharnstoff derivaten durch medikamente: II. Pharmakokinetik
und metabolismus von glibenclamid (HB 419) in gegenwart von
phenylbutazon</strong>. Eur J Clin Pharmacol 1971; 4:32-37.</li>
<li style="text-align: justify;">Schuna AA, Vejraska BD, Hiatt JG et
al. <strong>Lack of interaction between sulindac or naproxen and
propranolol in hypertensive patients</strong>. J Clin Pharmacol
1989; 29:524-528.</li>
<li style="text-align: justify;">Seltzer HS. <strong>Drug induced
hypoglycemia</strong>. Endocrinol Metab Clin North Am 1989;
18:163-183.</li>
<li style="text-align: justify;">Shah SJ, Bhadnardar SD et Satoskar
RS. <strong>Drug interaction between chlorpropamide and
nonsteroidal anti-inflamatory drugs, ibuprofen and phenylbutazone</strong>.
Int J Clin Pharmacol Ther Toxicol 1984; 22:470-472.</li>
<li style="text-align: justify;">Sharpe CR et Franco EL. <strong>Use
of dipyrone during pregnancy and risk of Wilms� tumor</strong>.
Epidemiol 1996; 7:533-535.</li>
<li style="text-align: justify;">Sheiner PA, Mor E, Chodoff L et al. <strong>Acute
renal failure associated with the use of ibuprofen in two liver
transplant recipients on FK506</strong>. Transplantation 1994;
57:1132-1133.</li>
<li style="text-align: justify;">Shinar E et Hershko C. <strong>Causes
of agranulocytosis in a hospital population: identification of
dipyrone as an important causative agent</strong>. Israel J Med
Sci 1983; 19:225-229.</li>
<li style="text-align: justify;">Shionoiri H. <strong>Pharmacokinetic
drug interactions with ACE inhibitors</strong>. Clin Pharmacokinet
1993; 25:20-58.</li>
<li style="text-align: justify;">Singh RR, Malaviya AN, Pandey JN et
al. <strong>Fatal interaction between methotrexate and naproxen </strong>(letter).
Lancet 1986; 1:1390.</li>
<li style="text-align: justify;">Skeith KJ, Russell AS, Jamali F et
al. <strong>Lack of significant interaction between low dose
methotrexate and ibuprofen or flurbiprofen in patients with
arthritis</strong>. J Rheumatol 1990; 17:1008-1010.</li>
<li style="text-align: justify;">Slavetti A, Pedrinelli R, Magagna A
et al. <strong>Calcium antagonists: interactions in hypertension</strong>.
Am J Nephrol 1986; 6(suppl 1):95-99.</li>
<li style="text-align: justify;">Sommers DK, Kovarik JM, Meyer EC et
al. <strong>Effects of diclofenac on isradipine pharmacokinetics
and platelet aggregation in volunteers</strong>. Eur J Clin
Pharmacol 1993; 44:391-393.</li>
<li style="text-align: justify;">Stewart CF, Fleming RA, Arkin CR et
al. <strong>Coadministration of naproxen and low-dose methotrexate
in patients with rheumatoid arthritis</strong>. Clin Pharmacol
Ther 1990; 47:540-546.</li>
<li style="text-align: justify;">Stewart CF, Fleming RA, Germain BF et
al. <strong>Aspirin alters methotrexate disposition in rheumatoid
arthritis patients</strong>. Arthritis Rheum 1991; 34:1514-1520.</li>
<li style="text-align: justify;">Sturrock NDC, Lang CC et Struthers
AD. <strong>Indomethacin and cyclosporin together produce marked
renal vasoconstriction in humans</strong>. J Hypertens 1994;
12:919-924.</li>
<li style="text-align: justify;">Sturrock ND et Struthers AD.<strong>
Non-steroidal anti-inflammatory drugs and angiotensive converting
enzyme inhibitors: a commonly prescribed combination with variable
effects on renal function</strong>. Br J Clin Pharmacol 1993;
35:343-348.</li>
<li style="text-align: justify;">Tempel G, von Hundelshausen B et
Reeker W. <strong>The opiate-sparing effect of dipyrone in
post-operative pain therapy with morphine using a
patient-controlled analgesic system</strong>. Intensive Care Med
1996; 22:1043-1047.</li>
<li style="text-align: justify;">Tempero KF, Cirillo VJ et Steelman
SL. <strong>Diflunisal: a review of pharmacokinetic and
pharmacodynamic properties, drug interactions, and special
tolerability studies in humans</strong>. Br J Clin Pharmacol 1977;
4(suppl 1):31S-36S.</li>
<li style="text-align: justify;">Thyss A, Milano G, Kubar J et al. <strong>Clinical
and pharmacokinetic evidence of a life-threatening interaction
between methotrexate and ketoprofen</strong>. Lancet 1986;
1:256-258.</li>
<li style="text-align: justify;">Tigerstedt I, Leander P et Tammisto
T. <strong>Postoperative analgesics for superficial surgery:
comparison of four analgesics</strong>. Acta Anaesth Scand 1981;
25:543-547.</li>
<li style="text-align: justify;">Todd PA et Sorkin EM. <strong>Diclofenac:
a reappraisal</strong>. Drugs 1988; 35:244-285.</li>
<li style="text-align: justify;">Tracy TS, Worster T, Bradley JD et
al: <strong>Methotrexate disposition following concomitant
administration of ketoprofen, piroxicam and flurbiprofen in
patients with rheumatoid arthritis</strong>. Br J Clin Pharmacol
1994; 37:453-456.</li>
<li style="text-align: justify;">TRISSEL, Lawrence <strong>A.
Handbook on injectable drugs</strong>. 10 ed. Houston, TX-USA:
ASHP 1998.</li>
<li style="text-align: justify;">Tugwell P, Ludwin D, Gent M et al. <strong>Interaction
between cyclosporin A and nonsteroidal antiinflammatory drugs</strong>.
J Rheumatol 1997; 24:1122-1125.</li>
<li style="text-align: justify;">van der Klauw MM, Wilson JHP et
Stricker BHC. <strong>Drug-associated agranulocytosis: 20 years of
reporting in the netherlands (1974-1994)</strong>. Am J Hematol
1998; 57:206-211.</li>
<li style="text-align: justify;">Vlahov V, Badian M, Verho M et al. <strong>Pharmacokinetics
of metamizol metabolites in healthy subjects after a single oral
dose of metamizol sodium</strong>. Eur J Clin Pharmacol 1990;
38:61-65.</li>
<li style="text-align: justify;">Volz M et Kellner HM. <strong>Kinetics
and metabolism of pyrazolones (propyphenazone, aminopyrine and
dipyrone). </strong>Br J Clin Pharmacol 1980; 10:299S-308S.</li>
<li style="text-align: justify;">von Szeged AV et Michos N. <strong>Controlled
single-blind clinical study of suprofen syrup versus metamizole
syrup</strong>. Arzneimittelforschung 1986; 36:1110-1112.</li>
<li style="text-align: justify;">Walbridge DG et Bazire SR.<strong> An
interaction between lithium carbonate and piroxicam presenting as
lithium toxicity</strong>. Br J Psychiatry 1985; 145:206-207.</li>
<li style="text-align: justify;">Watkins J, Abbott EC, Hensby CN et
al. <strong>Attenuation of hypotensive effect of propranolol and
thiazide diuretics by indomethacin. </strong>Br Med J 1980;
281:702-705.</li>
<li style="text-align: justify;">Weale AE, Warwick DJ, Durant N et al.<strong>
Is there a clinical interaction between low molecular weight
heparin and non-steroidal analgesics after total hip replacement?
</strong>Ann
R Coll Surg Engl 1995; 77:35-37.</li>
<li style="text-align: justify;">Webster J, Petrie JC, McLean I et al.
<strong>Flurbiprofen interaction with single doses of atenolol and
propranolol</strong>. Br J Clin Pharmacol 1984; 18:861-866.</li>
<li style="text-align: justify;">Weinberg MS, Quigg RJ, Salant DJ et
al.<strong> Anuric renal failure precipitated by indomethacin and
triamterene</strong>. Nephron 1985; 40:216-218.</li>
<li style="text-align: justify;">Whiting B, Williams RL, Lorenzi M et
al.<strong> Effect of naproxen on glucose metabolism and tolbutamide
kinetics and dynamics in maturity onset diabetes. </strong>Br J
Clin Pharmacol 1981; 11:295-302.</li>
<li style="text-align: justify;">Williams RL, Davies RO, Berman RS et
al. <strong>Hydrochlorothiazide pharmacokinetics and pharmacologic
effect: the influence of indomethacin</strong>. J Clin Pharmacol
1982; 22:32-41.</li>
<li style="text-align: justify;">Wong DG, Spence JD, Lamki L et al.<strong>
Effect of non-steroidal anti-inflammatory drugs on control of
hypertension by beta-blockers and diuretics. </strong>Lancet
1986; 1:997-1001.</li>
<li style="text-align: justify;">Wright JT, McKenney JM, Lehany AM et
al. <strong>The effect of high-dose short-term ibuprofen on
antihypertensive control with hydrochlorothiazide. </strong>Clin
Pharmacol Ther 1989; 46:440-444.</li>
<li style="text-align: justify;">Zylber-Katz E, Granit L et Levy M. <strong>Plasma
protein binding of dipyrone metabolites in man</strong>. Eur J
Clin Pharmacol 1985; 29:67-71.</li>
<li style="text-align: justify;">Zylber-Katz E, Linder N, Granit L et
al. <strong>Excretion of dipyrone metabolites in human breast milk</strong>.
Eur J Clin Pharmacol 1986; 30:359-361.</li>
</ol>
<div style="text-align: right;"><a href="javascript:window.print()"><img
style="border: 0px solid ; width: 18px; height: 18px;" alt="Imprimir"
title="Imprimir" src="../img/print.png"></a></div>
<div style="text-align: center;">[<a href="javascript:history.go(-1)">Voltar</a>]<br>
</div>
<span style="font-weight: bold;"></span></div>
</div>
<div id="footer"></div>
<br>
</body>
</html>
